Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine

被引:21
|
作者
Beulz-Riché, D
Grudé, P
Puozzo, C
Sautel, F
Filaquier, C
Riché, C
Ratanasavanh, D [1 ]
机构
[1] CHU Cavale Blanche, Serv Pharmacol, F-29285 Brest, France
[2] CHU Cavale Blanche, Serv Pharmacol & Pharmacovigilance, F-29285 Brest, France
[3] Inst Rech Pierre Fabre, Castres, France
关键词
CYP3A4; drug metabolism; liver microsomes; vinorelbine;
D O I
10.1111/j.1472-8206.2005.00367.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vinorelbine (VRL) (IV Navelbine((R))) is a semi-synthetic vinca alkaloid, used in therapeutics for the treatment of non-small-cell lung cancer and advanced breast cancer. The aim of this study was to characterize the cytochrome P450 (CYP) isoenzymes involved in VRL metabolism. VRL was incubated at 1.28 x 10(-5) M for 90 min with human hepatic microsomes prepared from 14 donors (one woman and 13 men aged from 27 to 76 years old) and characterized for CYP1A2, CYP2D6, CYP2E1 and CYP3A4 activities. A four-combined-approach study was performed, including correlation between CYP activities and VRL metabolism among the 14 batches of microsomes, inhibition of VRL biotransformation by isoform-selective substrates and by specific inhibitory antibodies, and incubation with supersomes((R)). Analysis of unchanged VRL and its metabolites was performed using an HPLC method coupled with both radioactive and UV detections. No correlation between CYP1A2 or CYP2E1 and VRL metabolism was observed in the 14 batches of microsomes used. A correlation was shown between VRL metabolism and CYP3A4 activity as determined with the dextromethorphan N-demethylase and nifedipine oxidase activities (r(2) = 0.80 and 0.59, respectively). These results were strengthened by a correlation between the metabolism extent of VRL and CYP3A4 protein content determined by immunoblotting (r(2) = 0.75). Furthermore, VRL biotransformation was inhibited by troleandomycine, the CYP3A4-specific inhibitor substrate (80% of inhibition) and by anti-CYP3A antibodies (36% of inhibition). On the contrary, a low correlation with CYP2D6 activity as determined by dextrometorphan O-demethylation (r(2) = 0.31) was established. CYP2D6 supersomes((R)) did not metabolize the drug whereas 63.4% of VRL were metabolized by microsomes overexpressing CYP3A4 isoform. These data indicated that CYP3A4 is the main enzyme involved in the hepatic metabolism of VRL in human, whereas CYP2D6 is not involved.
引用
收藏
页码:545 / 553
页数:9
相关论文
共 50 条
  • [21] Cytochrome P450 Enzymes and Drug Metabolism in Humans
    Zhao, Mingzhe
    Ma, Jingsong
    Li, Mo
    Zhang, Yingtian
    Jiang, Bixuan
    Zhao, Xianglong
    Huai, Cong
    Shen, Lu
    Zhang, Na
    He, Lin
    Qin, Shengying
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [22] Roles of Cytochrome P450 in Metabolism of Ethanol and Carcinogens
    Guengerich, F. Peter
    Avadhani, Narayan G.
    ALCOHOL AND CANCER, 2018, 1032 : 15 - 35
  • [23] The SMARTCyp cytochrome P450 metabolism prediction server
    Rydberg, Patrik
    Gloriam, David E.
    Olsen, Lars
    BIOINFORMATICS, 2010, 26 (23) : 2988 - 2989
  • [24] Molecular Modeling of Cytochrome P450 and Drug Metabolism
    Wang, Jing-Fang
    Chou, Kuo-Chen
    CURRENT DRUG METABOLISM, 2010, 11 (04) : 342 - 346
  • [25] Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: Focusing on CYP2A6
    Narimatsu, Shizuo
    Nakanishi, Ryoko
    Hanioka, Nobumitsu
    Saito, Keita
    Kataoka, Hiroyuki
    CHEMICO-BIOLOGICAL INTERACTIONS, 2011, 194 (2-3) : 120 - 126
  • [26] Utility of recombinant cytochrome P450 enzymes: A drug metabolism perspective
    Tang, W
    Wang, RW
    Lu, AYH
    CURRENT DRUG METABOLISM, 2005, 6 (05) : 503 - 517
  • [27] Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2
    Guo, Jingchao
    Zhu, Xiaohui
    Badawy, Sara
    Ihsan, Awais
    Liu, Zhenli
    Xie, Changqing
    Wang, Xu
    CURRENT DRUG METABOLISM, 2021, 22 (01) : 40 - 49
  • [28] Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes
    Froehlich, Eleonore
    Kueznik, Tatjana
    Samberger, Claudia
    Roblegg, Eva
    Wrighton, Christopher
    Pieber, Thomas R.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2010, 242 (03) : 326 - 332
  • [29] Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization
    Peter T. Doohan
    Lachlan D. Oldfield
    Jonathon C. Arnold
    Lyndsey L. Anderson
    The AAPS Journal, 23
  • [30] Luminogenic cytochrome P450 assays
    Cali, James J.
    Ma, Dongping
    Sobol, Mary
    Simpson, Daniel J.
    Frackman, Susan
    Good, Troy I.
    Daily, William J.
    Liu, David
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (04) : 629 - 645